From: Facile synthesis of multi-faceted, biomimetic and cross-protective nanoparticle-based vaccines for drug-resistant Shigella: a flexible platform technology
Encapsulants
%Encapsulation efficiency
%Loading
Assay
Amount of encapsulant in NPs used for vaccination (µg/mg NP)
LPS
16.1
0.4
TBA
4.0
IpaC
21.7
1.0
BCA
10.0
IpaB
60.0
3.1
31.0